{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-263316","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2021-09-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.153117+00:00","generated_at":"2026-06-29T06:34:43.709365+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Dermata appoints Kyri Van Hoose as CFO; Thomas Insley resigns, becomes consultant","bullets":["Kyri Van Hoose appointed SVP, CFO effective Sept 1, 2021; previously CFO at TEGA Therapeutics.","Thomas Insley resigned as CFO but remains as financial consultant via consulting agreement.","Van Hoose granted stock options for 75,000 shares at $5.39, vesting over 48 months from Oct 1, 2021.","Insley served as CFO for 6 years; transition supports continued development of DMT310 and DMT410."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-263316","json":"https://secwatch.observer/filing/0001193125-21-263316.json","markdown":"https://secwatch.observer/filing/0001193125-21-263316.md","text":"https://secwatch.observer/filing/0001193125-21-263316.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000119312521263316/0001193125-21-263316-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000119312521263316/d227068d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T06:34:43.709365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0c2c4a7b7d","claim":"Kyri Van Hoose was appointed as Senior Vice President, Chief Financial Officer at Dermata Therapeutics, Inc..","evidence_excerpt":"appointed Kyri Van Hoose as Senior Vice President, Chief Financial Officer, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1853816/000119312521263316/0001193125-21-263316-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President, Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"49a708dd38","claim":"Thomas Insley resigned as Chief Financial Officer at Dermata Therapeutics, Inc..","evidence_excerpt":"On September 1, 2021, Thomas Insley resigned as Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1853816/000119312521263316/0001193125-21-263316-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}